Abstract
The 2016 World Health Organization (WHO) classification of central nervous system (CNS) tumours heralded a shift towards an integrated diagnosis for brain tumours, incorporating both histological features and molecular data.1 This was re-iterated in 2018 by the Consortium to Inform Molecular and Practical Approaches to CNS Tumour Taxonomy (c-IMPACT).2 It is now recognised that a tumour's molecular phenotype not only assists in classification, but also provides prognostic information and impacts clinical management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
